These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
417 related articles for article (PubMed ID: 21358348)
1. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy. Hoda MA; Mohamed A; Ghanim B; Filipits M; Hegedus B; Tamura M; Berta J; Kubista B; Dome B; Grusch M; Setinek U; Micksche M; Klepetko W; Berger W J Thorac Oncol; 2011 May; 6(5):852-63. PubMed ID: 21358348 [TBL] [Abstract][Full Text] [Related]
2. Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma. Moriya M; Yamada T; Tamura M; Ishikawa D; Hoda MA; Matsumoto I; Klepetko W; Oda M; Yano S; Watanabe G Oncol Rep; 2014 Mar; 31(3):1109-15. PubMed ID: 24378576 [TBL] [Abstract][Full Text] [Related]
3. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro. Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118 [TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth. Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936 [TBL] [Abstract][Full Text] [Related]
5. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma. Pignochino Y; Dell'Aglio C; Inghilleri S; Zorzetto M; Basiricò M; Capozzi F; Canta M; Piloni D; Cemmi F; Sangiolo D; Gammaitoni L; Soster M; Marchiò S; Pozzi E; Morbini P; Luisetti M; Aglietta M; Grignani G; Stella GM BMC Cancer; 2015 May; 15():374. PubMed ID: 25952930 [TBL] [Abstract][Full Text] [Related]
6. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma. Hartman ML; Esposito JM; Yeap BY; Sugarbaker DJ J Thorac Cardiovasc Surg; 2010 May; 139(5):1233-40. PubMed ID: 19853261 [TBL] [Abstract][Full Text] [Related]
7. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma. Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744 [TBL] [Abstract][Full Text] [Related]
8. The essential role of the mitochondria and reactive oxygen species in Cisplatin-mediated enhancement of fas ligand-induced apoptosis in malignant pleural mesothelioma. Stewart JH; Tran TL; Levi N; Tsai WS; Schrump DS; Nguyen DM J Surg Res; 2007 Jul; 141(1):120-31. PubMed ID: 17574045 [TBL] [Abstract][Full Text] [Related]
9. The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma. Laszlo V; Valko Z; Ozsvar J; Kovacs I; Garay T; Hoda MA; Klikovits T; Stockhammer P; Aigner C; Gröger M; Klepetko W; Berger W; Grusch M; Tovari J; Waizenegger IC; Dome B; Hegedus B J Mol Med (Berl); 2019 Feb; 97(2):231-242. PubMed ID: 30539198 [TBL] [Abstract][Full Text] [Related]
10. Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts. Littlejohn JE; Cao X; Miller SD; Ozvaran MK; Jupiter D; Zhang L; Rodarte C; Smythe WR Int J Cancer; 2008 Jul; 123(1):202-8. PubMed ID: 18360826 [TBL] [Abstract][Full Text] [Related]
11. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. Kanteti R; Riehm JJ; Dhanasingh I; Lennon FE; Mirzapoiazova T; Mambetsariev B; Kindler HL; Salgia R Sci Rep; 2016 Sep; 6():32992. PubMed ID: 27623107 [TBL] [Abstract][Full Text] [Related]
12. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma. Iwahori K; Serada S; Fujimoto M; Ripley B; Nomura S; Mizuguchi H; Shimada K; Takahashi T; Kawase I; Kishimoto T; Naka T Int J Cancer; 2013 Jan; 132(2):459-71. PubMed ID: 22532243 [TBL] [Abstract][Full Text] [Related]
13. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells. Zanellato I; Colangelo D; Osella D Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341 [TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo. Miyoshi S; Hamada H; Hamaguchi N; Kato A; Katayama H; Irifune K; Ito R; Miyazaki T; Okura T; Higaki J Int J Oncol; 2012 Aug; 41(2):449-56. PubMed ID: 22580933 [TBL] [Abstract][Full Text] [Related]
15. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma. Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Jänne PA; Taffaro ML; Salgia R; Johnson BE Cancer Res; 2002 Sep; 62(18):5242-7. PubMed ID: 12234991 [TBL] [Abstract][Full Text] [Related]
17. Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma. Iwahori K; Serada S; Fujimoto M; Nomura S; Osaki T; Lee CM; Mizuguchi H; Takahashi T; Ripley B; Okumura M; Kawase I; Kishimoto T; Naka T Int J Cancer; 2011 Aug; 129(4):1005-17. PubMed ID: 20949562 [TBL] [Abstract][Full Text] [Related]
18. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864 [TBL] [Abstract][Full Text] [Related]
19. Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Fung AS; Wu L; Tannock IF Clin Cancer Res; 2009 Sep; 15(17):5389-95. PubMed ID: 19706800 [TBL] [Abstract][Full Text] [Related]
20. Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma. Volta V; Ranzato E; Martinotti S; Gallo S; Russo MV; Mutti L; Biffo S; Burlando B PLoS One; 2013; 8(3):e58051. PubMed ID: 23526965 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]